ABVC BioPharma, Inc. (NASDAQ:ABVC) Short Interest Down 22.7% in March

ABVC BioPharma, Inc. (NASDAQ:ABVC) saw a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 321,400 shares, a decrease of 22.7% from the February 28th total of 415,800 shares. Currently, 2.9% of the company’s stock are short sold. Based on an average daily volume of 490,100 shares, the short-interest ratio is presently 0.7 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in ABVC BioPharma stock. Avantax Planning Partners Inc. grew its holdings in ABVC BioPharma, Inc. (NASDAQ:ABVC) by 269.1% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 143,968 shares of the company’s stock after buying an additional 104,968 shares during the period. Avantax Planning Partners Inc. owned 1.11% of ABVC BioPharma worth $85,000 at the end of the most recent reporting period. 11.38% of the stock is currently owned by institutional investors and hedge funds.

ABVC BioPharma Trading Up 7.6 %

Shares of ABVC opened at $0.86 on Monday. The firm’s fifty day simple moving average is $0.60 and its 200-day simple moving average is $0.58. The firm has a market capitalization of $11.16 million, a price-to-earnings ratio of -1.00 and a beta of 0.67. ABVC BioPharma has a twelve month low of $0.40 and a twelve month high of $1.73.

ABVC BioPharma Company Profile

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.